Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion

Cancer Research

Volumn 65, Issue 20, 2005, Pages 9113-9116

  Colombo, Mario P ^a,b   Mantovani, Alberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL INTERACTION; CELL SURVIVAL; CHRONIC INFLAMMATION; EFFECTOR CELL; EXTRACELLULAR MATRIX; INFLAMMATION; LEUKEMIA CELL; MYELOMONOCYTIC LEUKEMIA; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; REVIEW; TARGET CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR PROMOTION;

ANIMALS; HUMANS; INFLAMMATION; MACROPHAGES; MICE; NEOPLASMS;

EID: 27144558287     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2714     Document Type: Review

References (22)

1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
3. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7: 211-7.
4. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
5. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351: 2817-26.
6. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8.
7. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004;113:1040-50.
8. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004;114:623-33.
9. Allavena P, Signorelli M, Chieppa M, et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005;65: 2964-71.
10. Burnett SH, Kershen EJ, Zhang J, et al. Conditional macrophage ablation in transgenic mice ex-pressing a Fas-based suicide gene. J Leukoc Biol 2004;75:612-23.
11. Greten FR, Eckmann L, Greten TF, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
12. Pikarsky E, Porat RM, Stein I, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-6.
13. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005;65:3437-46.
14. De Santo C, Serafini P, Marigo I, et al. Nitro-aspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A 2005;102:4185-90.
15. Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med 2004;10:15-8.
16. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11:312-9.
17. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 23-dioxygenase. Nat Med 2003;9:1269-74.
18. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A 2003;100:2645-50.
19. Sangaletti S, Stoppacciaro A, Guiducci C, Torrisi MR, Colombo MP. Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. J Exp Med 2003;198:1475-85.
20. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005;7:411-23.
21. Mantovani A. Cancer: inflammation by remote control. Nature 2005;435:752-3.
22. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005;65:3967-79.